Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet.

Trial Profile

Open-Label, Randomized, Single-Dose, 2-Way Crossover Bioequivalence Study Comparing A New Alprazolam Sublingual Tablet Formulation To A Reference Alprazolam Immediate Release Tablet.

Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 29 May 2012

At a glance

  • Drugs Alprazolam; Alprazolam
  • Indications Generalised anxiety disorder; Panic disorder
  • Focus Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 23 Feb 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Planned end date changed from 1 Mar 2011 to 1 Jun 2011 as reported by ClinicalTrials.gov.
    • 10 Feb 2011 Planned initiation date changed from 1 Jan 2011 to 1 Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top